19.6.2005
News

Ongoing Developments in the Area of Borderline Products

Directive of the European Parliament No. 2004/27EC of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (OJ EU [2004], L 136, p. 34)

Scientific progress and the development of new types of products explain the rise in issues regarding the legal qualification of so-called “borderline” products. Borderline product issues usually arise with regard to products having combined characteristics of medicines and foods, of medicines and medical devices and/or medicines and cosmetics.

A new Directive (hereinafter the “Directive”) – which amends the directive establishing a Community code for human medicines) – is due to be implemented by the Member States by October 2005 amends the definition of “medicinal product” and introduces new principles to determine which of rules should apply in case of uncertainty. Firstly, the amended definition of “medicinal product” is now broader, to encompass, for instance, gene therapy and radiopharmaceutical products:

(a)    Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or

(b)    Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis (Article 1(2) of the Directive)[emphasis added]

Secondly, the Directive introduces a provision stating that if a product fits the definition of a medicinal product and, at the same time, the definition of another category of product (for instance a food), pharmaceutical rules apply, so, in this sense, prevails.

Separately, the summary of a European Commission workshop on the same topics released recently as well as other discussions announce further developments regarding borderline products.

In the area of foods, a draft regulation on nutrition and health claims made on foods is being discussed. Separately, it is worth noting that a draft regulation regarding the addition of vitamins and minerals and of certain other substances to foods is also under discussion.

In the area of medical devices, the European Commission foresees updating of existing guidelines. Further, the European Commission is considering whether to issue a communication on the legal principles and relevant methods with regard to the classification of products.

Other articles

13.10.2025
News

Contract Competition 2025

KŠB ve spolupráci s největší nezávislou asociací studentů práv na světě ELSA vyhlašuje již 14. ročník soutěže CONTRACT COMPETITION. Soutěž studentům práv nabízí jedinečný pohled do světa transakčního práva pod vedením advokátů přední české advokátní kanceláře.
12.10.2025
Financial services

KŠB assisted the J&T Group with the approval of a base prospectus for a CZK 3 billion bond programme

The KŠB team (Martin Krejčí, Vlastimil Pihera, Josef Kříž) provided legal advice to the J&T Group in connection with the approval of the base prospectus for its bond programme. This marks a continuation of KŠB’s long-term advisory role in the group’s financing activities.
9.10.2025
Financial services

KŠB assisted in financing the iconic Alchymist Grand Hotel and Spa

KŠB has been providing long-term legal advice to J&T Bank in connection with debt financing for Czech entrepreneurs. One of the most recent transactions involved granting a loan to the Alchymist Grand Hotel and Spa, one of Prague’s most renowned boutique hotels, owned by Giorgio Bonelli, a prominent figure in the Italian business community in the Czech Republic.